<![CDATA[Pyrazinamide and ethambutol are essential components of anti-tuberculosis therapy; however, both drugs can affect uric acid metabolism and increase the risk of hyperuricemia. Elevated uric acid levels may potentially cause joint pain and other metabolic disorders that can affect patient adherence to therapy. This study aims to analyze changes in serum uric acid levels before and after the administration of pyrazinamide–ethambutol combination therapy in tuberculosis patients. The study employed a retrospective analytical observational design using secondary data from the medical records of tuberculosis patients undergoing treatment at three type D regional general hospitals in West Jakarta. A sample of 100 patients was selected using a total sampling method. Data analysis was performed using descriptive statistics and a paired-samples t-test. The results showed an increase in the mean serum uric acid levels in both male and female patients after four weeks of therapy. Male patients had higher uric acid levels than females, although the increase was significant in both groups. These findings suggest that pyrazinamide–ethambutol combination therapy leads to an increase in serum uric acid levels during the intensive phase of tuberculosis treatment. Therefore, regular monitoring of uric acid levels is essential for early detection of hyperuricemia and for optimizing patient management in tuberculosis.]]>
Copyrights © 2026
